Breaking Finance News

TheStreet downgraded Myokardia Inc (NASDAQ:MYOK) to D+ in a statement released earlier today.

Yesterday Myokardia Inc (NASDAQ:MYOK) traded 2.35% higher at $13.65. The company’s 50-day moving average is $44.65 and its 200-day moving average is $40.06. The last stock close price is down 14.19% from the 200-day moving average, compared to the S&P 500 which has increased 0.01% over the same time. 133,151 shares of the stock were exchanged, down from an average trading volume of 476,517

TheStreet has downgraded Myokardia Inc (NASDAQ:MYOK) to D+ in a statement released on Friday May 19, 2017.

See Chart Below

Myokardia Inc (NASDAQ:MYOK)

Myokardia Inc has a 52 week low of $10.55 and a 52 week high of $46.90 The company’s market cap is currently $0.

About Myokardia Inc (NASDAQ:MYOK)

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.